Protagonist Therapeutics, Inc (PTGX) Dividend History

Company News

• Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

  Protagonist Therapeutics and Takeda Pharmaceutical's investigational drug rusfertide met its primary endpoint in a late-stage study for polycythemia vera, a type of blood cancer. The drug showed a significantly higher proportion of clinical responders compared to placebo.

  Benzinga
• BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment

  BESREMi, a FDA-approved treatment for polycythemia vera, is gaining market share due to its potential for better tolerability and lower risk of treatment-related malignancies compared to competitors like ruxolitinib and hydroxyurea.

  GlobeNewswire Inc.

  Featured Companies: ABBV BMY GSKH IONS MRK
• Polycythemia Vera Market Insight, Epidemiology and Market Forecast, 2034: JAKAFI & BESREMi Lead Polycythemia Vera Market, But New Therapies Poised to Disrupt by 2034

  The Polycythemia Vera market is expected to grow significantly by 2034, driven by the launch of new therapies and increased healthcare spending. JAKAFI and BESREMi currently lead the market, but upcoming drugs like rusfertide, bomedemstat, and DUVYZAT have the potential to disrupt the landscape.

  GlobeNewswire Inc.
• All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy

  Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  Zacks Investment Research
• Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet

  The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  Zacks Investment Research